April 8 (Reuters) - Incyte Corp :
   * LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3 COV-BARRIER STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
   * INCYTE CORP - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 1,525 PATIENTS DID NOT MEET STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
   * INCYTE - DATA SHOWED 38% REDUCTION IN MORTALITY BY DAY 28 IN PATIENTS TREATED WITH BARICITINIB IN ADDITION TO STANDARD OF CARE
   * INCYTE CORP - FREQUENCY OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
   * INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO USE OF BARICITINIB WERE IDENTIFIED
   * INCYTE CORP - TRIAL SHOWED LARGEST EFFECT REPORTED TO DATE FOR REDUCTION IN MORTALITY OBSERVED FOR THIS CERTAIN PATIENT POPULATION WITH COVID-19

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)